Roche has committed to a $50 billion investment in pharmaceuticals and diagnostics in the U.S. over the next five years, joining a host of drugmakers who have announced similar initiatives amid concerns about the impact of possible tariffs on imported pharma goods.
As part of the investment, Roche will increase its existing footprint of more than 25,000 employees in 24 sites across eight U.S. states. The initiative is expected to create more than 12,000 new jobs, including nearly 6,500 construction jobs, as well as 1,000 jobs at new and expanded facilities.
The investment will include:
- Expanded and upgraded U.S. manufacturing and distribution capabilities for Roche’s innovative medicines and diagnostics portfolio in Kentucky, Indiana, New Jersey, Oregon and California
- A state-of-the-art gene therapy manufacturing facility in Pennsylvania
- A new 900,000-square-foot manufacturing center to support Roche’s expanding portfolio of next generation weight loss medicines (location to be announced)
- A new manufacturing facility for continuous glucose monitoring in Indiana
- A new R&D center in Massachusetts, conducting AI research and serving as hub for the company’s new cardiovascular, renal and metabolism research and development efforts
- Significant expansion and upgrading of existing pharmaceuticals and diagnostics R&D centers in Arizona, Indiana and California.
The move comes as drugmakers look to bolster their U.S. presence amid threats from President Trump that a “major tariff on pharmaceuticals” is coming “shortly.” Earlier this month, Novartis unveiled a planned $23 billion investment over five years in U.S.-based infrastructure. Eli Lilly announced in February that will invest $27 billion to construct four manufacturing sites in the U.S, three of which will focus on small molecule production.